Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Vaccine - Page 41

Vaccine

Biological E Limited started phase I/II clinical trial of its COVID-19 vaccine candidate
COVID-19 | Life Science History | Vaccine

Biological E Limited started phase I/II clinical trial of its COVID-19 vaccine candidate

On Nov. 16, 2020, Biological E. Limited (BE), a Hyderabad-based vaccines and pharmaceutical company, Dynavax Technologies, and Baylor…

Read More Biological E Limited started phase I/II clinical trial of its COVID-19 vaccine candidateContinue

Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures

On Nov. 16, 2020, Moderna announced new data showing that mRNA-1273, its COVID-19 vaccine candidate, remained stable at…

Read More Moderna announced longer shelf life for its COVID-19 vaccine candidate at refrigerated temperaturesContinue

Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Vaccine

Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidate

On Nov. 16, 2020, Tonix Pharmaceuticals announced preliminary results following vaccination of non-human primates with TNX-1800 (modified horsepox…

Read More Tonix Pharmaceuticals reported positive immune response results from COVID-19 Vaccine candidateContinue

BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in China
Life Science History | Vaccine

BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in China

On Nov. 16, 2020, BioNTech and Shanghai Fosun Pharmaceutica announced that the China National Medical Products Administration had…

Read More BioNTech and Fosun Pharma approved to commence COVID-19 vaccine candidate BNT162b2 trial in ChinaContinue

INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800
Biotechnology | COVID-19 | FDA | Infectious Disease | Vaccine

INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800

On Nov. 16, 2020, INOVIO announced that it had received clearance from the the U.S. Food & Drug…

Read More INOVIO announced initiation of phase 2/3 clinical trial for COVID-19 DNA vaccine candidate, INO-4800Continue

European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Vaccine

European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19

On Nov. 16, 2020, Moderna announced that the European Medicines Agency (EMA) human medicines committee (CHMP) had started…

Read More European Medicines Agency began rolling review of Moderna’s mRNA vaccine candidate against COVID-19Continue

Johnson & Johnson Initiated second global phase 3 clinical trial of Janssen COVID-19 vaccine candidate
COVID-19 | Life Science History | Vaccine

Johnson & Johnson Initiated second global phase 3 clinical trial of Janssen COVID-19 vaccine candidate

On Nov. 15, 2020, Johnson & Johnson announced that it continued to enroll and vaccinate study participants for…

Read More Johnson & Johnson Initiated second global phase 3 clinical trial of Janssen COVID-19 vaccine candidateContinue

Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
Biotechnology | COVID-19 | Infectious Disease | Life Science History | NIH | Vaccine

Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study

On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…

Read More Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE studyContinue

Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19

On Nov. 13, 2020, Moderna announced that Swissmedic had started a rolling review of mRNA-1273, the Company’s vaccine…

Read More Swissmedic began rolling review of Moderna’s mRNA vaccine against COVID-19Continue

CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics
Biotechnology | COVID-19 | Vaccine

CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics

On Nov. 12, 2020, CureVac announced that its mRNA-based COVID-19 vaccine candidate, CVnCoV, remained stable and within defined…

Read More CureVac’s COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logisticsContinue

Gates Foundation announced funds to develop COVID-19 vaccines and increase access in low-income countries
COVID-19 | Non-Profit Research | Vaccine

Gates Foundation announced funds to develop COVID-19 vaccines and increase access in low-income countries

On Nov. 12, 2020, the Bill & Melinda Gates Foundation announced new commitments totaling $70 million to global…

Read More Gates Foundation announced funds to develop COVID-19 vaccines and increase access in low-income countriesContinue

Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccine
Life Science History | Vaccine

Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccine

On Nov. 12, 2020 Vaxart announced additional results from its Hamster Challenge Study. The study evaluated Vaxartメs recombinant…

Read More Vaxart announced additional data from Hamster Challenge Study of its oral COVID-19 vaccineContinue

Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2
Biotechnology | COVID-19 | Therapeutics | Vaccine

Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2

On Nov. 11, 2020, Sorrento Therapeutics announced that it was filing an investigational new drug application (IND) for…

Read More Sorrento announced IND filing for COVI-DROPS against SARS-CoV-2Continue

COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum Institute
Biotechnology | Infectious Disease | Vaccine

COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum Institute

On Nov. 11, 2020, the Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) announced…

Read More COVISHIELD completed enrollment of phase III clinical trials under partnership of ICMR and Serum InstituteContinue

Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine

Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19

On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…

Read More Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19Continue

Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2
Life Science History | Vaccine

Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2

On Nov. 11, 2020, Pfizer and BioNTech announced that they had reached an agreement with the European Commission…

Read More Pfizer and BioNTech to supply the EU with 200 million doses of mRNA-based vaccine against SARS-CoV-2Continue

Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2
Biotechnology | COVID-19 | Therapeutics | Vaccine

Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2

On Nov. 19, 2020, Medigen Vaccine Biologics and BlueWillow Biologics announced a partnership to develop S-2P-NE-01, a nasal…

Read More Medigen Vaccines and BlueWillow Biologics partnered to Develop intranasal vaccine for SARS-COV-2Continue

ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study
COVID-19 | Life Science History | Vaccine

ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose study

On Nov. 10, 2020, ImmunityBio and NantKwest, a clinical-stage, natural killer cell-based therapeutics company, announced they had administered…

Read More ImmunityBio, NantKwest announced positive interim phase 1 safety data of hAd5 COVID-19 vaccine dose studyContinue

Altimmune added Lonza as manufacturing partner for supply of AdCOVIDル vaccine candidate for COVID-19
COVID-19 | Life Science History | Vaccine

Altimmune added Lonza as manufacturing partner for supply of AdCOVIDル vaccine candidate for COVID-19

On Nov. 10, 2020, Altimmune announced an agreement with Lonza for the manufacturing of AdCOVIDル, Altimmuneメs next-generation, single-dose…

Read More Altimmune added Lonza as manufacturing partner for supply of AdCOVIDル vaccine candidate for COVID-19Continue

Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study
Biotechnology | COVID-19 | Therapeutics | Vaccine

Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 study

On Nov. 9, 2020, Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence…

Read More Pfizer and BioNTech announced vaccine candidate against COVID-19 achieved success in interim analysis from phase 3 studyContinue

Fred Hutch began experimental COVID-19 vaccine efficacy trial
COVID-19 | Diagnostics | Infectious Disease | Vaccine

Fred Hutch began experimental COVID-19 vaccine efficacy trial

On Nov. 9, 2020, the Fred Hutchinson Cancer Research Center announced the start of volunteer enrollment for a…

Read More Fred Hutch began experimental COVID-19 vaccine efficacy trialContinue

ImmunityBioメs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2
COVID-19 | Life Science History | Vaccine

ImmunityBioメs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2

On Nov. 8, 2020, ImmunityBio announced positive study results for their human Ad5 (hAd5) COVID-19 vaccine candidate, which…

Read More ImmunityBioメs hAd5 COVID-19 vaccine candidate stimulated memory T-Cell recall in patients with SARS-CoV-2Continue

Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccine

On Nov. 4, 2020, Novavax announced the signing of a non-binding Heads of Terms document with the Australian…

Read More Novavax and Commonwealth of Australia announced agreement for acquisition of Novavax COVID-19 vaccineContinue

Medigen Vaccines and NIHE partnered to develop COVID-19 vaccine in Vietnam
Biotechnology | COVID-19 | Medicine | NIH | Therapeutics | Vaccine

Medigen Vaccines and NIHE partnered to develop COVID-19 vaccine in Vietnam

On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…

Read More Medigen Vaccines and NIHE partnered to develop COVID-19 vaccine in VietnamContinue

Novavax announced facility expansion to support global vaccine development
Biotechnology | COVID-19 | Infectious Disease | Influenza | Vaccine

Novavax announced facility expansion to support global vaccine development

On Nov. 2, 2020, Novavax announced the expansion of its Maryland campus to accommodate the company’s rapid growth…

Read More Novavax announced facility expansion to support global vaccine developmentContinue

CureVac reported positive interim phase 1 data for COVID-19 vaccine candidate
Life Science History | Vaccine

CureVac reported positive interim phase 1 data for COVID-19 vaccine candidate

On Nov. 2, 2020, CureVac announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the…

Read More CureVac reported positive interim phase 1 data for COVID-19 vaccine candidateContinue

Kaiser Permanente Research Institute enrolled volunteers in a phase 3 clinical trial to evaluate COVID-19 vaccine
Biotechnology | COVID-19 | Vaccine

Kaiser Permanente Research Institute enrolled volunteers in a phase 3 clinical trial to evaluate COVID-19 vaccine

On Oct. 30, 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced enrollment of volunteers in a phase…

Read More Kaiser Permanente Research Institute enrolled volunteers in a phase 3 clinical trial to evaluate COVID-19 vaccineContinue

Trials of University of Oxford’s Coronavirus vaccine began in Kenya
COVID-19 | Life Science History | Vaccine

Trials of University of Oxford’s Coronavirus vaccine began in Kenya

On Oct. 30, 2020, the University of Oxford announced that Kenya had joined the global efforts in search…

Read More Trials of University of Oxford’s Coronavirus vaccine began in KenyaContinue

Icosavax launched COVID-19 vaccine program with preclinical data and $165 million in new funding
COVID-19 | Life Science History | Vaccine

Icosavax launched COVID-19 vaccine program with preclinical data and $165 million in new funding

On Oct. 30, 2020, Icosavax announced the launch of the companyメs COVID-19 vaccine program with preclinical data on…

Read More Icosavax launched COVID-19 vaccine program with preclinical data and $165 million in new fundingContinue

Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19

On Oct. 29, 2020, Takeda Pharmaceutical announced that it would import and distribute 50 million doses of Moderna’s…

Read More Moderna partnered with Takeda and Government of Japan to supply 50 million doses of mRNA vaccine against COVID-19Continue

Page navigation

Previous PagePrevious 1 … 39 40 41 42 43 … 73 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search